We are in the midst of a paradigm shift in how cancer can be diagnosed and treated. The combination of targeted therapies and precise diagnostics is allowing for the era of personalized medicine to emerge. The capture and enrichment of circulating tumor cells is going to be a critical element of targeted companion diagnostics. We believe our next generation CTC capture system will allow the full diagnostic potential of CTCs to finally be realized.
Chairman of the Board
CEO & Board Member
Legal, Secretary & Board Member
Vortex Biosciences Inc, is a core subsidiary of NetScientific plc, a transatlantic biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at http://www.netscientific.net
Openings may be available in other areas as the company expands. So, if you are interested in an entrepreneurial role with opportunity for growth, if you are passionate about new technologies for improving overall health, if you want to be a part of unlocking the challenges of early cancer detection, we encourage you to contact us.
For more information or to apply, fill out the form provided or email us at email@example.com.
Life Science Research Associate
Vortex Biosciences is advancing the fight against cancer, and its mission is to be the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives. Shed by tumors into the circulation, Circulating Tumor Cells (CTCs) offer a window into cancer biology. However, the capture of CTCs from blood is not easy as CTCs are relatively scarce, with concentration as low as 1-10 CTCs/mL of whole blood, against a background of millions of white blood cells and billions of red blood cells. The Vortex technology makes this simple, automating the capture and collection of clinically relevant, viable CTCs directly from whole blood. We have recently released the VTX-1 Liquid Biopsy System to the research market, designed to rapidly isolate CTCs from blood for further downstream analysis.
The R&D team is seeking a highly motivated individual to support the development and validation of cell-based assays. The candidate will be working within multidisciplinary team of scientists, cell and molecular biologists, research collaborators, as well as mechanical engineers to characterize the VTX-1 for cancer diagnostic applications.
A competitive compensation package, commensurate with experience, is offered for this position. This package includes a competitive base salary, stock options, bonus, paid-off time, medical, dental and other benefits.
This position is to be filled immediately.
For more information about this opportunity please visit http://www.vortexbiosciences.com and contact us.